Research Area COVID-19 and Mpox

A5407 - Ensayo ambulatorio de fase 3 controlado con placebo del agente Shionogi para el tratamiento de la infección sintomática por SARS-CoV-2

Closed to accrual

See locations

A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies

A master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with…

Closed to accrual

28 days of intensive follow-up, followed by limited follow-up through 24 weeks.

See locations

A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Subsequent Vaccine

Right now there is no medicine proven to treat COVID-19 in people who are not sick enough to be hospitalized.…

Closed to accrual

See locations

A5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Disease

A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease.

Open and enrolling

See locations